Holen Sie sich die Stockscreener-App
66.75
3.42%
2.21
Handel nachbörslich:
66.75
Schlusskurs vom Vortag:
$64.54
Offen:
$65.24
24-Stunden-Volumen:
684.78K
Relative Volume:
0.55
Marktkapitalisierung:
$5.53B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
8.628
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
-0.37%
1M Leistung:
-1.49%
6M Leistung:
+15.40%
1J Leistung:
+18.62%
1-Tages-Spanne:
$64.88
$67.45
1-Wochen-Bereich:
$64.00
$69.02
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
66.75 | 5.34B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Appoints Jessica Chutter To Board - citybiz
PTC Therapeutics Adds Veteran Banker to Board - TipRanks
Ptc Therapeutics appoints biotech banking pioneer Jessica Chutter to board of directors - marketscreener.com
PTC Therapeutics, Inc. Appoints Jessica Chutter to Board of Directors - marketscreener.com
PTC Therapeutics appoints Jessica Chutter to its board - TradingView
Biotech banker Jessica Chutter joins PTC Therapeutics (NASDAQ: PTCT) board - Stock Titan
PTC Therapeutics adds Jessica Chutter to board of directors - Investing.com
Morgan Stanley biotech banker tied to $80B raises joins PTC board - Stock Titan
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Rating Updates - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeut - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
Fundamentals Check: How sensitive is PTC Therapeutics Inc to inflationPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative - simplywall.st
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (PTCT) CEO logs RSU vesting and automatic tax share sale - Stock Titan
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile - Sahm
Insider Sell: Stephanie Okey Sells 15,167 Shares of PTC Therapeu - GuruFocus
Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Director Sells Over $1 Million in Company Stock - TradingView
PTC Therapeutics (PTCT) director exercises options, sells 15,167 shares - Stock Titan
PTCT (NASDAQ: PTCT) insider reports proposed 2,662-share sale - Stock Titan
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
FDA ‘blacklist’ in DMD? Legislator slams PTC turndown - bioworld.com
PTC Therapeutics at Barclays Conference: Sephience’s Global Potential By Investing.com - Investing.com Canada
PTCT: Sepiapterin’s rapid PKU launch drives strong growth, with global expansion and pipeline progress - TradingView
PTCT Earnings History & Surprises | EPS & Revenue Results | PTC THERAPEUTICS INC (NASDAQ:PTCT) - ChartMill
PTC Therapeutics Stock Soars 8.88%, Hits Intraday High of $69.17 - Markets Mojo
PTC Therapeutics at Leerink Conference: Strategic Growth in PKU Market By Investing.com - Investing.com Canada
Proposed sale: 15,167 PTCT shares listed by Fidelity (PTCT) - Stock Titan
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally - Trefis
(PTCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stephanie Okey Sells 6,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Neil Gregory Almstead Sells 3,989 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 6,333 shares at $63.38 - Stock Titan
Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer - Stock Titan
PTC Therapeutics (PTCT) CTO spouse sells shares under 10b5-1 trading plan - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9%Time to Buy? - MarketBeat
Jefferies Financial Group Acquires Stake in PTC Therapeutics - National Today
Jefferies Financial Group Inc. Acquires Shares of 1,584,678 PTC Therapeutics, Inc. $PTCT - MarketBeat
Ideas Watch: Will PTC Therapeutics Inc. benefit from government policy2026 Setups & Safe Entry Trade Signal Reports - baoquankhu1.vn
Dividend Watch: Is PTC Therapeutics Inc a stock for growth or value investorsMarket Volume Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):